2024 AACR (oral): Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile. From concept to clinic.

View Presentation:
2024 AACR (oral): Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile. From concept to clinic

 

2024 AACR (poster): Identification of biomarkers of response to MDM2 inhibition in solid tumours using computational, multi-omics approaches.

View Poster:
2024 AACR (poster): Identification of biomarkers of response to MDM2 inhibition in solid tumours using computational, multi-omics approaches

 

 

2024 AACR (poster): Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53

View Poster:
2024 AACR (poster): Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53

 

2024 AACR (poster): Targeting the MDM2-p53 interaction: Time-and concentration-dependent studies in tumor and normal human bone marrow cells reveal strategies for an enhanced therapeutic index

View Poster:
2024 AACR (poster): Targeting the MDM2-p53 interaction: Time-and concentration-dependent studies in tumor and normal human bone marrow cells reveal strategies for an enhanced therapeutic index

 

Henderikx et al., “VitroJet: new features and case studies”; Structural Biology. 2024

Henderikx et al., “VitroJet: new features and case studies”; Structural Biology. 2024

https://journals.iucr.org/d/issues/2024/04/00/ih5005/index.html

Day et al., “Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2)”; J. Med. Chem. 2024

Day et al., “Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2)”; J. Med. Chem. 2024

https://doi.org/10.1021/acs.jmedchem.3c02118

EORTC Poster (2022): Low SKP2 expression is predictive of sensitivity to an MDM2 antagonist in p53 wild-type AML

View Poster:
Low Skp2 expression is predictive of sensitivity to an MDM2 antagonist in p53 wild-type AML

Woodhead et al., “Fragment-to-Lead Medicinal Chemistry Publications in 2022”; J. Med. Chem. 2024

Woodhead et al., “Fragment-to-Lead Medicinal Chemistry Publications in 2022”; J. Med. Chem. 2024

https://doi.org/10.1021/acs.jmedchem.3c02070

Townley et al., “Enabling synthesis in fragment-based drug discovery (FBDD): microscale high-throughput optimisation of the medicinal chemist’s toolbox reactions”; RSC Med. Chem.2023

Townley et al., “Enabling synthesis in fragment-based drug discovery (FBDD): microscale high-throughput optimisation of the medicinal chemist’s toolbox reactions”; RSC Med. Chem.2023

https://doi.org/10.1039/D3MD00495C

2023 AACR-NCI-EORTC (poster): Identifying Sensitive Patient Populations for CDK7 Inhibitors Using Cell Panel Screens and Bioinformatic Approaches

View Poster:
2023 AACR-NCI-EORTC (poster): Identifying Sensitive Patient Populations for CDK7 Inhibitors Using Cell Panel Screens and Bioinformatic Approaches